On May 17, the U.S. Food and Drug Administration (FDA) expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis (CF), tripling the number of rage gene mutations the drug can now treat. Read more
Most Recent Content
For Nurse Practitioners
Menopause and Sleep Problems
Data shows that sleep disturbances increase in prevalence during the menopausal transition, with the most common complaint being nighttime awakenings.
Take our quick three-question survey...
